Abstract
We investigated a case of the unexpectedly high clozapine/norclozapine serum levels in a non-smoker, female patient. The RFLP genotype method was used for the loss-of-function CYP450 gene polymorphisms detection. The genotype revealed the presence of CYP2D6*41/*41, rs28371725, NM_000106.5:c.985+39G>A and CYP1A2*1/*1D rs35694136, NM_000761.4:c.-1635delT. An appropriate clozapine serum level is required for both optimization of clinical response and avoidance of troublesome, or even life-threatening side effects. Although not the only factor, genetic polymorphisms responsible for the metabolism of clozapine play an important role towards such goals. Pharmacogenetic tests can guide dose adjustment in order to obtain an optimum serum level, which can lead to a better therapeutic response and minimization of harmful side effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
